Platform
Features
NextPhase Therapeutics
Contact
Carlos Paya is a board member of two publicly listed companies (NYSE and NASDAQ). He was President and CEO, Immune Design Corp, until its acquisition by Merck.
9 members
Elysium Therapeutics, Inc.
Molecular Partners
Pacific Edge
Genmab
AbSci